PMV PHARMACEUTICALS, INC. Research and Development Expense
PMV PHARMACEUTICALS, INC. (PMVP) reported Research and Development Expense of $14.68 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- PMV PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-06-30 was $14.68M, a 20.24% decline year-over-year.
- PMV PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-03-31 was $15.33M, a 12.10% decline year-over-year.
- PMV PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-12-31 was $15.83M, a 14.96% increase year-over-year.
- PMV PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-09-30 was $18.21M, a 7.45% increase year-over-year.
- PMV PHARMACEUTICALS, INC. research and development expense for fiscal 2025 was $69.88M, a 19.39% increase from fiscal 2024.
- PMV PHARMACEUTICALS, INC. research and development expense for fiscal 2024 was $58.53M, a 4.73% increase from fiscal 2023.
- PMV PHARMACEUTICALS, INC. research and development expense for fiscal 2023 was $55.88M, a 7.50% increase from fiscal 2022.
- PMV PHARMACEUTICALS, INC. research and development expense for fiscal 2022 was $51.99M, a 42.46% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.68M 10-Q · filed 2026-08-14 | $30.01M 10-Q · filed 2026-08-14 | $45.83M derived: sum of 3 quarters · filed 2026-08-14 | $64.04M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $15.33M 10-Q · filed 2026-05-12 | $31.16M derived: sum of 2 quarters · filed 2026-05-12 | $49.37M derived: sum of 3 quarters · filed 2026-05-12 | $67.77M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $15.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $34.04M derived: sum of 2 quarters · filed 2026-03-06 | $52.44M derived: sum of 3 quarters · filed 2026-08-14 | $69.88M 10-K · filed 2026-03-06 |
| 2025-09-30 | $18.21M 10-Q · filed 2025-11-12 | $36.61M derived: sum of 2 quarters · filed 2026-08-14 | $54.05M 10-Q · filed 2025-11-12 | $67.82M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $18.40M 10-Q · filed 2026-08-14 | $35.84M 10-Q · filed 2026-08-14 | $49.61M derived: sum of 3 quarters · filed 2026-08-14 | $66.56M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $17.44M 10-Q · filed 2026-05-12 | $31.21M derived: sum of 2 quarters · filed 2026-05-12 | $48.16M derived: sum of 3 quarters · filed 2026-05-12 | $62.78M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $13.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $30.71M derived: sum of 2 quarters · filed 2026-03-06 | $45.34M derived: sum of 3 quarters · filed 2026-03-06 | $58.53M 10-K · filed 2026-03-06 |
| 2024-09-30 | $16.95M 10-Q · filed 2025-11-12 | $31.57M derived: sum of 2 quarters · filed 2025-11-12 | $44.76M 10-Q · filed 2025-11-12 | $58.14M derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-06-30 | $14.63M 10-Q · filed 2025-08-07 | $27.81M 10-Q · filed 2025-08-07 | $41.20M derived: sum of 3 quarters · filed 2026-03-06 | $54.78M derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-03-31 | $13.19M 10-Q · filed 2025-05-09 | $26.57M derived: sum of 2 quarters · filed 2026-03-06 | $40.15M derived: sum of 3 quarters · filed 2026-03-06 | $54.00M derived: sum of 4 quarters · filed 2026-03-06 |
| 2023-12-31 | $13.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $26.97M derived: sum of 2 quarters · filed 2026-03-06 | $40.81M derived: sum of 3 quarters · filed 2026-03-06 | $55.88M 10-K · filed 2026-03-06 |
| 2023-09-30 | $13.59M 10-Q · filed 2024-11-07 | $27.43M derived: sum of 2 quarters · filed 2024-11-07 | $42.50M 10-Q · filed 2024-11-07 | $57.53M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $13.84M 10-Q · filed 2024-08-08 | $28.92M 10-Q · filed 2024-08-08 | $43.94M derived: sum of 3 quarters · filed 2025-03-03 | $57.61M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $15.07M 10-Q · filed 2024-05-09 | $30.10M derived: sum of 2 quarters · filed 2025-03-03 | $43.76M derived: sum of 3 quarters · filed 2025-03-03 | $55.23M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $15.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $28.69M derived: sum of 2 quarters · filed 2025-03-03 | $40.15M derived: sum of 3 quarters · filed 2025-03-03 | $51.99M 10-K · filed 2025-03-03 |
| 2022-09-30 | $13.67M 10-Q · filed 2023-11-09 | $25.13M derived: sum of 2 quarters · filed 2023-11-09 | $36.96M 10-Q · filed 2023-11-09 | $49.13M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $11.46M 10-Q · filed 2023-08-09 | $23.30M 10-Q · filed 2023-08-09 | $35.47M derived: sum of 3 quarters · filed 2024-02-29 | $44.63M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $11.84M 10-Q · filed 2023-05-10 | $24.00M derived: sum of 2 quarters · filed 2024-02-29 | $33.16M derived: sum of 3 quarters · filed 2024-02-29 | $40.83M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $12.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $21.33M derived: sum of 2 quarters · filed 2024-02-29 | $28.99M derived: sum of 3 quarters · filed 2024-02-29 | $36.49M 10-K · filed 2024-02-29 |
| 2021-09-30 | $9.16M 10-Q · filed 2022-11-08 | $16.83M derived: sum of 2 quarters · filed 2022-11-08 | $24.33M 10-Q · filed 2022-11-08 | $30.51M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $7.66M 10-Q · filed 2022-08-09 | $15.16M 10-Q · filed 2022-08-09 | $21.34M derived: sum of 3 quarters · filed 2023-03-01 | $27.34M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $7.50M 10-Q · filed 2022-05-10 | $13.68M derived: sum of 2 quarters · filed 2023-03-01 | $19.67M derived: sum of 3 quarters · filed 2023-03-01 | $25.48M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $6.18M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $12.17M derived: sum of 2 quarters · filed 2023-03-01 | $17.98M derived: sum of 3 quarters · filed 2023-03-01 | $23.93M 10-K · filed 2023-03-01 |
| 2020-09-30 | $5.99M 10-Q · filed 2021-11-12 | $11.80M derived: sum of 2 quarters · filed 2021-11-12 | $17.75M 10-Q · filed 2021-11-12 | $23.45M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $5.80M 10-Q · filed 2021-08-13 | $11.76M 10-Q · filed 2021-08-13 | $17.46M derived: sum of 3 quarters · filed 2022-03-01 | $22.35M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $5.96M 10-Q · filed 2021-05-14 | $11.65M derived: sum of 2 quarters · filed 2022-03-01 | $16.55M derived: sum of 3 quarters · filed 2022-03-01 | |
| 2019-12-31 | $5.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $10.59M derived: sum of 2 quarters · filed 2022-03-01 | $20.76M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $4.89M 10-Q · filed 2020-11-13 | $15.06M 10-Q · filed 2020-11-13 | ||
| 2018-12-31 | $13.85M 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |